How can ribavirin cause pneumothorax?

Ribavirin and Pneumothorax: Causation Mechanism

Ribavirin does not directly cause pneumothorax; if pneumothorax occurs during ribavirin therapy, it is almost always due to the underlying lung disease or iatrogenic factors rather than a direct drug effect. 1, 2

• Guideline framing

  • ECIL-4 and pediatric guidelines list ribavirin adverse effects (bronchospasm, declining pulmonary function; hemolysis systemically) but do not identify pneumothorax as a ribavirin toxicity, supporting no direct causal link to pleural air leak syndromes 1.
  • BTS pneumothorax guidelines identify common iatrogenic/clinical causes (procedures, ventilation, necrotizing infections like PCP) and do not implicate antivirals such as ribavirin 2.

• Plausible indirect pathways (rare, inferential)

  • Aerosolized ribavirin can trigger bronchospasm and transient airflow obstruction; in severely diseased or ventilated lungs this could raise intrathoracic pressures and theoretically precipitate barotrauma-related pneumothorax, but this is not documented as a recognized adverse event in guidelines or the FDA label 1, 3.
  • Interferon-associated interstitial pneumonitis (when ribavirin is coadministered for HCV) can cause diffuse lung injury; pneumothorax could occur secondarily from fragile, inflamed parenchyma, yet published cases attribute the lung toxicity to interferon, not ribavirin itself 4, 5, 6.

• Drug-label safety signal

  • FDA label for inhaled ribavirin highlights bronchospasm and pulmonary function decline, not pneumothorax; animal data note inflammatory/emphysematous changes with high-dose exposure, but human relevance is unknown and pneumothorax is not listed 3.

• Practical algorithm to protect morbidity, mortality, QOL

  • If pneumothorax develops on ribavirin:
    • Treat pneumothorax per BTS guidelines (oxygen, aspiration, or chest drain as indicated; be vigilant for tension physiology) 2.
    • Search for actual cause: recent procedures (biopsy, central line), positive-pressure ventilation, necrotizing infections (e.g., PCP), cystic/bullous disease 2.
    • Continue or hold ribavirin based on respiratory stability:
      • Continue if clear benefit expected (e.g., severe RSV in high-risk host) and no evidence that ribavirin worsened the event; monitor for bronchospasm and lung function 1.
      • Hold if significant bronchospasm or unexplained pulmonary decline temporally linked to dosing, and reassess risk-benefit (especially when safer alternatives or supportive care suffice) 1.
  • Avoid pitfall: misattributing a procedure- or ventilation-related pneumothorax to ribavirin; this risks withholding antiviral therapy without reducing recurrence risk 2.

• Bottom line

  • No high-quality, recent guideline or FDA evidence supports ribavirin as a direct cause of pneumothorax; observed cases should trigger evaluation for common etiologies and careful continuation decisions to minimize mortality and preserve quality of life 1, 2, 3.